Effect of Duloxetine 30/60 mg Once Daily Versus Placebo in Adolescents With Juvenile Primary Fibromyalgia Syndrome
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Duloxetine (Primary)
- Indications Fibromyalgia
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly
- 12 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Mar 2017 Planned End Date changed from 31 Oct 2017 to 1 Dec 2017.
- 08 Mar 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.